Locally advanced squamous cell carcinoma of the head and neck (SCCHN) is treated with various
combinations of radiation and chemotherapy. This study aims to evaluate the rate of complete
responses with induction therapy (primary endpoint) and progression-free survival, overall
survival and objective response rates of docetaxel, cisplatin, cetuximab, and bevacizumab
(TPE-A) followed by radiation therapy, cisplatin, cetuximab, and bevacizumab (XPE-A). Also,
the investigators plan to investigate a panel of EGFR and angiogenesis biomarkers in pre-and
post- treatment tumor biopsies. Finally, the investigators will evaluate the associated
treatment toxicities and the quality of life.